TELIX Pharmaceuticals Ltd (TLX) - Net Assets

Latest as of June 2025: AU$421.94 Million AUD ≈ $298.55 Million USD

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has net assets worth AU$421.94 Million AUD (≈ $298.55 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$1.19 Billion ≈ $841.97 Million USD) and total liabilities (AU$768.01 Million ≈ $543.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check TLX financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$421.94 Million
% of Total Assets	35.46%
Annual Growth Rate	18.83%
5-Year Change	619.11%
10-Year Change	N/A
Growth Volatility	649.22

TELIX Pharmaceuticals Ltd - Net Assets Trend (2000–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore total assets of TELIX Pharmaceuticals Ltd for the complete picture of this company's asset base.

Annual Net Assets for TELIX Pharmaceuticals Ltd (2000–2024)

The table below shows the annual net assets of TELIX Pharmaceuticals Ltd from 2000 to 2024. For live valuation and market cap data, see how much is TELIX Pharmaceuticals Ltd worth.

Year	Net Assets	Change
2024-12-31	AU$568.21 Million ≈ $402.05 Million	+281.58%
2023-12-31	AU$148.91 Million ≈ $105.36 Million	+93.60%
2022-12-31	AU$76.92 Million ≈ $54.42 Million	+2011.97%
2021-12-31	AU$3.64 Million ≈ $2.58 Million	-95.39%
2020-12-31	AU$79.02 Million ≈ $55.91 Million	+11.71%
2019-12-31	AU$70.73 Million ≈ $50.05 Million	+33.70%
2018-12-31	AU$52.90 Million ≈ $37.43 Million	+7.33%
2017-12-31	AU$49.29 Million ≈ $34.88 Million	+445.15%
2000-12-31	AU$9.04 Million ≈ $6.40 Million	--

Equity Component Analysis

This analysis shows how different components contribute to TELIX Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 20688300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Common Stock	AU$596.78 Million	105.03%
Other Comprehensive Income	AU$184.40 Million	32.45%
Total Equity	AU$568.21 Million	100.00%

TELIX Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their market capitalization.

Company	Market Cap
Nickel Industries Ltd AU:NIC	$3.27 Billion
Brookdale Senior Living Inc NYSE:BKD	$3.27 Billion
Adecco Group AG F:ADIA	$3.28 Billion
Acerinox MC:ACX	$3.28 Billion
National Storage Affiliates Trust NYSE:NSA	$3.27 Billion
Dorman Products Inc NASDAQ:DORM	$3.27 Billion
Clicks JSE:CLS	$3.27 Billion
China Baoan Group Co Ltd SHE:000009	$3.26 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in TELIX Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 148,911,000 to 568,213,000, a change of 419,302,000 (281.6%).
Net income of 49,919,000 contributed positively to equity growth.
Share repurchases of 999,000 reduced equity.
New share issuances of 999,000 increased equity.
Other comprehensive income increased equity by 218,091,000.
Other factors increased equity by 151,292,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	AU$49.92 Million	+8.79%
Share Repurchases	AU$999.00K	-0.18%
Share Issuances	AU$999.00K	+0.18%
Other Comprehensive Income	AU$218.09 Million	+38.38%
Other Changes	AU$151.29 Million	+26.63%
Total Change	AU$-	281.58%

Book Value vs Market Value Analysis

This analysis compares TELIX Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 9.46x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 66.58x to 9.46x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2000-12-31	AU$0.23	AU$15.57	x
2017-12-31	AU$0.39	AU$15.57	x
2018-12-31	AU$0.26	AU$15.57	x
2019-12-31	AU$0.30	AU$15.57	x
2020-12-31	AU$0.31	AU$15.57	x
2021-12-31	AU$0.01	AU$15.57	x
2022-12-31	AU$0.26	AU$15.57	x
2023-12-31	AU$0.46	AU$15.57	x
2024-12-31	AU$1.65	AU$15.57	x

Capital Efficiency Dashboard

This dashboard shows how efficiently TELIX Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 8.79%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 6.37%
• Asset Turnover: 0.52x
• Equity Multiplier: 2.67x
Recent ROE (8.79%) is above the historical average (-443.30%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2000	-5.50%	0.00%	0.00x	1.04x	AU$-1.40 Million
2017	-12.94%	-1580.58%	0.01x	1.04x	AU$-11.31 Million
2018	-26.14%	-7087.06%	0.00x	1.45x	AU$-19.12 Million
2019	-39.76%	-799.63%	0.03x	1.46x	AU$-34.88 Million
2020	-56.81%	-861.06%	0.03x	2.00x	AU$-52.79 Million
2021	-3730.77%	-1059.90%	0.07x	50.89x	AU$-80.73 Million
2022	-130.09%	-65.01%	0.63x	3.19x	AU$-112.08 Million
2023	3.50%	1.04%	1.26x	2.67x	AU$-9.68 Million
2024	8.79%	6.37%	0.52x	2.67x	AU$-6.90 Million

Industry Comparison

This section compares TELIX Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $11,537,405
Average return on equity (ROE) among peers: -124.60%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
TELIX Pharmaceuticals Ltd (TLX)	AU$421.94 Million	-5.50%	1.82x	$3.27 Billion
Adalta Ltd (1AD)	$172.82K	-722.64%	1.66x	$8.12 Million
Algorae Pharmaceuticals Ltd (1AI)	$8.43 Million	-80.40%	0.15x	$20.04 Million
ACRUX Ltd (ACR)	$43.92 Million	-0.55%	0.08x	$3.49 Million
Actinogen Medical Ltd (ACW)	$21.74 Million	-43.69%	0.07x	$103.45 Million
Argenica Therapeutics Ltd (AGN)	$8.31 Million	-49.24%	0.09x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$19.30 Million	-17.45%	0.18x	$66.62 Million
Anatara Lifesciences Ltd (ANR)	$5.92 Million	-48.49%	0.08x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$-80.67K	0.00%	0.00x	$80.80 Million
Amplia Therapeutics Ltd (ATX)	$6.07 Million	-40.21%	0.29x	$54.45 Million
Avecho Biotechnology Ltd (AVE)	$1.59 Million	-243.30%	0.02x	$31.19 Million

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.69 Billion

AU$5.21 Billion AUD

Market Cap Rank

#4679 Global

#115 in Australia

Share Price

AU$15.57

Change (1 day)

+3.80%

52-Week Range

AU$8.63 - AU$29.16

All Time High

AU$31.14